Nuvation Bio Inc 短期资本化租赁债务 : $ 1.97 (2023年12月 最新)
Nuvation Bio Inc短期资本化租赁债务(Short-Term Capital Lease Obligation)的相关内容及计算方法如下:
短期资本化租赁债务表示必须在一年或一个营业周期内支付的 长期资本租赁负债 总额。资本租赁负债是通过资本租赁合同获得对财产或设备的使用而产生的合同义务。
截至2023年12月, Nuvation Bio Inc 过去一季度 的 短期资本化租赁债务 为 $ 1.97。
点击上方“历史数据”快速查看Nuvation Bio Inc 短期资本化租赁债务的历史走势;
点击上方“解释说明”快速查看关于Nuvation Bio Inc 短期资本化租赁债务的详细说明;
点击上方“相关词条”快速查看与短期资本化租赁债务相关的其他指标。
Nuvation Bio Inc 短期资本化租赁债务 (NUVB.WS 短期资本化租赁债务) 历史数据
Nuvation Bio Inc 短期资本化租赁债务的历史年度,季度/半年度走势如下:
Nuvation Bio Inc 短期资本化租赁债务 年度数据 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
日期 | 2020-12 | 2021-12 | 2022-12 | 2023-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
短期资本化租赁债务 | - | 0.86 | 1.21 | 1.97 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nuvation Bio Inc 短期资本化租赁债务 季度数据 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
日期 | 2021-09 | 2021-12 | 2022-03 | 2022-06 | 2022-09 | 2022-12 | 2023-03 | 2023-06 | 2023-09 | 2023-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
短期资本化租赁债务 | - | 0.86 | 0.70 | 0.94 | 1.10 | 1.21 | 1.24 | 1.28 | 1.92 | 1.97 |
Nuvation Bio Inc 短期资本化租赁债务 (NUVB.WS 短期资本化租赁债务) 解释说明
短期资本化租赁债务表示必须在一年或一个营业周期内支付的 长期资本租赁负债 总额。资本租赁负债是通过资本租赁合同获得对财产或设备的使用而产生的合同义务。
Nuvation Bio Inc 短期资本化租赁债务 (NUVB.WS 短期资本化租赁债务) 相关词条
感谢查看价值大师中文站为您提供的Nuvation Bio Inc短期资本化租赁债务的详细介绍,请点击以下链接查看与Nuvation Bio Inc短期资本化租赁债务相关的其他词条:
Nuvation Bio Inc (NUVB.WS) 公司简介
一级行业:医疗保健
二级行业:生物科技
公司网站:https://www.nuvationbio.com
公司地址:1500 Broadway, Suite 1401, New York, NY, USA, 10036
公司简介:Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
二级行业:生物科技
公司网站:https://www.nuvationbio.com
公司地址:1500 Broadway, Suite 1401, New York, NY, USA, 10036
公司简介:Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).